keyword
MENU ▼
Read by QxMD icon Read
search

Levomilnacipran

keyword
https://www.readbyqxmd.com/read/27861191/effects-of-levomilnacipran-extended-release-on-major-depressive-disorder-patients-with-cognitive-impairments-post-hoc-analysis-of-a-phase-iii-study
#1
Keith A Wesnes, Carl Gommoll, Changzheng Chen, Angelo Sambunaris, Roger S McIntyre, Philip D Harvey
Performance-based cognitive data were collected using the Cognitive Drug Research System in a study of levomilnacipran extended-release (ER) 40-120 mg/day (NCT01034462) in adults with major depressive disorder. These data were analyzed post-hoc to explore the relationship between cognitive measures, depression symptoms (Montgomery-Åsberg Depression Rating Scale, MADRS), and self-reported psychosocial functioning (Sheehan Disability Scale; SDS). Changes from baseline were analyzed in the intent-to-treat population and subgroups with impaired attention, as indicated by baseline Cognitive Drug Research System scores for Power of Attention and Continuity of Attention...
November 16, 2016: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27822042/efficacy-and-safety-of-multiple-doses-of-levomilnacipran-extended-release-for-the-treatment-of-major-depressive-disorder
#2
Qunlian Huang, Xiaoyan Zhong, Ye Yun, Bin Yu, Yilan Huang
OBJECTIVE: The aim of this meta-analysis was to evaluate the efficacy and safety of levomilnacipran extended-release (ER) in the treatment of major depressive disorder (MDD). METHODS: Randomized controlled trials were searched by electronic databases. Unpublished data were also searched by the relevant websites. Weighted mean difference (WMD) and risk ratio (RR) with 95% confidence interval (CI) were calculated and pooled using fixed-effects model or random-effects model...
2016: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/27508501/the-safety-tolerability-and-risks-associated-with-the-use-of-newer-generation-antidepressant-drugs-a-critical-review-of-the-literature
#3
André F Carvalho, Manu S Sharma, André R Brunoni, Eduard Vieta, Giovanni A Fava
Newer generation antidepressant drugs (ADs) are widely used as the first line of treatment for major depressive disorders and are considered to be safer than tricyclic agents. In this critical review, we evaluated the literature on adverse events, tolerability and safety of selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, bupropion, mirtazapine, trazodone, agomelatine, vilazodone, levomilnacipran and vortioxetine. Several side effects are transient and may disappear after a few weeks following treatment initiation, but potentially serious adverse events may persist or ensue later...
2016: Psychotherapy and Psychosomatics
https://www.readbyqxmd.com/read/27455513/effects-of-levomilnacipran-extended-release-on-motivation-energy-and-functioning-in-adults-with-major-depressive-disorder
#4
Michael E Thase, Carl Gommoll, Changzheng Chen, Kenneth Kramer, Angelo Sambunaris
The objective of this post-hoc analysis was to investigate the relationship between motivation/energy and functional impairment in patients with major depressive disorder (MDD). Data were taken from a phase 3 trial of levomilnacipran extended-release (ER) in adults with MDD (NCT01034462; N=429) that used the 18-item Motivation and Energy Inventory (MEI) to assess motivation/energy. Two subgroups with lower and higher motivation/energy were defined using baseline MEI total scores (≤28 and >28, respectively)...
November 2016: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27401359/comparative-efficacy-and-acceptability-of-first-generation-and-second-generation-antidepressants-in-the-acute-treatment-of-major-depression-protocol-for-a-network-meta-analysis
#5
Toshi A Furukawa, Georgia Salanti, Lauren Z Atkinson, Stefan Leucht, Henricus G Ruhe, Erick H Turner, Anna Chaimani, Yusuke Ogawa, Nozomi Takeshima, Yu Hayasaka, Hissei Imai, Kiyomi Shinohara, Aya Suganuma, Norio Watanabe, Sarah Stockton, John R Geddes, Andrea Cipriani
INTRODUCTION: Many antidepressants are indicated for the treatment of major depression. Two network meta-analyses have provided the most comprehensive assessments to date, accounting for both direct and indirect comparisons; however, these reported conflicting interpretation of results. Here, we present a protocol for a systematic review and network meta-analysis aimed at updating the evidence base and comparing all second-generation as well as selected first-generation antidepressants in terms of efficacy and acceptability in the acute treatment of major depression...
2016: BMJ Open
https://www.readbyqxmd.com/read/27292817/the-efficacy-of-levomilnacipran-er-across-symptoms-of-major-depressive-disorder-a-post-hoc-analysis-of-5-randomized-double-blind-placebo-controlled-trials
#6
Roger S McIntyre, Carl Gommoll, Changzheng Chen, Adam Ruth
OBJECTIVE: A post hoc analysis evaluated the effects of levomilnacipran ER on individual symptoms and symptom domains in adults with major depressive disorder (MDD). METHODS: Data were pooled from 5 Phase III trials comprising 2598 patients. Effects on depression symptoms were analyzed based on change from baseline in individual Montgomery-Åsberg Depression Rating Scale (MADRS) item scores. A1dditional evaluations included resolution of individual symptoms (defined as a MADRS item score ≤1 at end of treatment) and concurrent resolution of all 10 MADRS items, all MADRS6 subscale items, and all items included in different symptom clusters (Dysphoria, Retardation, Vegetative Symptoms, Anhedonia)...
June 13, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27180420/levomilnacipran-a-successor-of-milnacipran-with-a-higher-noradrenergic-selectivity
#7
REVIEW
Łukasz Zadka, Ewelina Dziwota, Marcin Olajossy
A new antidepressant, levomilnacipran, is the levorotatory enantiomer of milnacipran. The drug belongs to selective serotonin-norepinephrine reuptake inhibitors (SNRI) and has the highest noradrenergic selectivity of all members of this group of antidepressants. Clinical trials have confirmed the effectiveness of levomilnacipran in the treatment of depression. The drug was placed on the US market in the form of prolonged-release capsules, which greatly simplifies the treatment of psychiatric patients. The safety of the drug is also higher than the safety of a racemate, resulting in a beneficial impact on the therapeutic effect...
March 2016: Acta Poloniae Pharmaceutica
https://www.readbyqxmd.com/read/27141705/levomilnacipran-and-vortioxetine-for-adults-with-major-depressive-disorder
#8
REVIEW
Jonathan R Scarff
No abstract text is available yet for this article.
December 2015: Journal of the South Carolina Medical Association
https://www.readbyqxmd.com/read/26967743/a-review-of-antidepressant-induced-urinary-hesitancy-a-focus-on-levomilnacipran-er-including-two-case-presentations-5633
#9
Gregory M Asnis, Elishka Caneva, Margaret A Henderson
INTRODUCTION: Levomilnacipran ER was recently FDA approved as Fetzima® for the treatment of MDD. Urinary hesitancy can be an adverse event associated with levomilnacipran treatment. AREAS COVERED: This manuscript details the longitudinal course of levomilnacipran-induced urinary hesitancy in 2 cases that were in a pivotal clinical trial, examining possible predisposing factors and treatment issues. This manuscript also reviews the literature comparing urinary hesitancy associated with levomilnacipran versus other antidepressants...
May 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/26938965/vortioxetine-for-major-depressive-disorder-an-indirect-comparison-with-duloxetine-escitalopram-levomilnacipran-sertraline-venlafaxine-and-vilazodone-using-number-needed-to-treat-number-needed-to-harm-and-likelihood-to-be-helped-or-harmed
#10
REVIEW
Leslie Citrome
BACKGROUND: Vortioxetine is approved for the treatment of major depressive disorder and differs from other antidepressants in terms of its pharmacodynamic profile. Given the limited number of head-to-head studies comparing vortioxetine with other antidepressants, indirect comparisons using effect sizes observed in other trials can be helpful to discern potential differences in clinical outcomes. METHODS: Data sources were the clinical trial reports for the pivotal short-term double-blind trials for vortioxetine and from publicly available sources for the pivotal short-term double-blind trials for two commonly used generic serotonin specific reuptake inhibitor antidepressants (sertraline, escitalopram), two commonly used generic serotonin-norepinephrine reuptake inhibitor antidepressants (venlafaxine, duloxetine), and two recently introduced branded antidepressants (vilazodone, levomilnacipran)...
May 15, 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/26773906/the-effects-of-levomilnacipran-er-in-adult-patients-with-first-episode-highly-recurrent-or-chronic-mdd
#11
RANDOMIZED CONTROLLED TRIAL
Susan G Kornstein, Carl Gommoll, Changzheng Chen, Kenneth Kramer
BACKGROUND: Major depressive disorder (MDD) can be challenging to manage due its variable and episodic nature. Post hoc analyses were conducted on five studies (NCT00969709, NCT01377194, NCT00969150, NCT01034462, EudraCT:2006-002404-34) to evaluate the efficacy of levomilnacipran extended-release (ER) in patients with different MDD episode histories. METHODS: Adults with MDD were randomized to double-blind treatment with levomilnacipran ER (40-120mg/d) or placebo...
March 15, 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/26700248/p-glycoprotein-differentially-affects-escitalopram-levomilnacipran-vilazodone-and-vortioxetine-transport-at-the-mouse-blood-brain-barrier-in%C3%A2-vivo
#12
Christoffer Bundgaard, Elin Eneberg, Connie Sánchez
P-glycoprotein (P-gp)-mediated brain efflux of xenobiotics is a well-known process, which may result in suboptimal target engagement and consequently reduced efficacy of drugs exerting their therapeutic effects in the central nervous system. In the present study the role of P-gp in transport across the blood-brain barrier (BBB) was investigated with a series of newer antidepressants (levomilnacipran, vilazodone and vortioxetine) and a control substrate (escitalopram) using P-gp knock-out (KO) and P-gp competent wild-type (WT) mice...
April 2016: Neuropharmacology
https://www.readbyqxmd.com/read/26644957/levomilnacipran-extended-release-treatment-in-patients-with-major-depressive-disorder-improvements-in-functional-impairment-categories
#13
Andrew J Cutler, Carl P Gommoll, Changzheng Chen, William M Greenberg, Adam Ruth
OBJECTIVE: In this post hoc analysis, improvement in functional impairment in patients with major depressive disorder (MDD) treated with levomilnacipran extended release (ER) was evaluated by assessing shifts from more severe to less severe functional impairment categories on individual Sheehan Disability Scale (SDS) subscales. METHOD: SDS data were pooled from 5 phase II/III studies conducted between December 2006 and March 2012 of levomilnacipran ER versus placebo in adult patients with MDD (DSM-IV-TR criteria)...
2015: Primary Care Companion to CNS Disorders
https://www.readbyqxmd.com/read/26584326/effects-of-levomilnacipran-er-on-fatigue-symptoms-associated-with-major-depressive-disorder
#14
Marlene P Freeman, Maurizio Fava, Carl Gommoll, Changzheng Chen, William M Greenberg, Adam Ruth
The aim of this study was to evaluate the effects of levomilnacipran extended-release (ER) on depression-related fatigue in adults with major depressive disorder. Post-hoc analyses of five phase III trials were carried out, with evaluation of fatigue symptoms based on score changes in four items: Montgomery-Åsberg Depression Rating Scale (MADRS) item 7 (lassitude), and 17-item Hamilton Depression Rating Scale (HAMD17) items 7 (work/activities), 8 (retardation), and 13 (somatic symptoms). Symptom remission was analyzed on the basis of score shifts from baseline to end of treatment: MADRS item 7 and HAMD17 item 7 (from ≥2 to ≤1); HAMD17 items 8 and 13 (from ≥1 to 0)...
March 2016: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/26572745/the-role-of-levomilnacipran-in-the-management-of-major-depressive-disorder-a-comprehensive-review
#15
Antonio Bruno, Paolo Morabito, Edoardo Spina, Maria Rosaria Muscatello
Levomilnacipran, the more active enantiomer of the serotonin and norepinephrine reuptake inhibitor (SNRI) milnacipran, was recently approved in the US for the treatment of major depressive disorder (MDD). The drug was developed as an extended release (ER) capsule formulation to allow for once-daily administration, thereby improving patient adherence. This agent differs from other available SNRIs in having a greater potency for inhibition of norepinephrine relative to serotonin reuptake. The efficacy of levomilnacipran ER has been evaluated in seven randomised, double-blind clinical trials (one Phase II and four Phase III trials, and two long-term efficacy studies)...
2016: Current Neuropharmacology
https://www.readbyqxmd.com/read/26554414/levomilnacipran-fetzima-for-major-depressive-disorder
#16
Samira Zaman, Maura R McLaughlin
No abstract text is available yet for this article.
October 15, 2015: American Family Physician
https://www.readbyqxmd.com/read/26546771/inclusion-exclusion-criteria-in-placebo-controlled-studies-of-vortioxetine-comparison-to-other-antidepressants-and-implications-for-product-labeling
#17
REVIEW
Mark Zimmerman, Heather L Clark, Matthew D Multach, Emily Walsh, Lia K Rosenstein, Douglas Gazarian
BACKGROUND: We recently conducted a comprehensive review of the psychiatric inclusion/exclusion criteria used in 170 placebo-controlled antidepressant efficacy trials (AETs) published during the past 20 years and found that the criteria of more recent studies were significantly more restrictive than prior studies. Vortioxetine is the most recently approved medication for the treatment of major depressive disorder (MDD). We compared the inclusion/exclusion criteria of the vortioxetine studies to the criteria used in other AETs, and discuss the broader issue of the generalizability of AETs and the implications this might have for the labeling of antidepressants receiving FDA approval...
January 15, 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/26464458/the-serotonergic-system-in-the-neurobiology-of-depression-relevance-for-novel-antidepressants
#18
REVIEW
Stephan Köhler, Katharina Cierpinsky, Golo Kronenberg, Mazda Adli
The monoamine hypothesis of depression posits that an imbalance in monoaminergic neurotransmission is causally related to the clinical features of depression. Antidepressants influencing serotonin mainly aim at raising serotonin concentrations, thereby increasing serotonergic transmission at the level of the synapse, for example by inhibiting the serotonin transporter. However, the serotonin system is multifaceted. Different serotonin receptor subtypes turn the serotonergic system into a complex neurochemical arrangement that influences diverse neurotransmitters in various brain regions...
January 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/26315684/evaluation-of-cytochrome-p450-cyp-3a4-based-interactions-of-levomilnacipran-with-ketoconazole-carbamazepine-or-alprazolam-in-healthy-subjects
#19
RANDOMIZED CONTROLLED TRIAL
Laishun Chen, Ramesh Boinpally, Nayra Gad, William M Greenberg, Julie Wangsa, Antonia Periclou, Parviz Ghahramani
BACKGROUND AND OBJECTIVES: Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor with balanced potency for the reuptake inhibition of norepinephrine and serotonin, approved in the USA for the treatment of major depressive disorder (MDD) in adults. We conducted studies in healthy human subjects to investigate pharmacokinetic interactions when levomilnacipran extended-release (ER) is administered in combination with an inhibitor (ketoconazole), an inducer (carbamazepine), or a substrate (alprazolam) of cytochrome P450 (CYP) 3A4...
October 2015: Clinical Drug Investigation
https://www.readbyqxmd.com/read/26256429/levomilnacipran-pharmacokinetics-in-healthy-volunteers-versus-patients-with-major-depressive-disorder-and-implications-for-norepinephrine-and-serotonin-reuptake-inhibition
#20
RANDOMIZED CONTROLLED TRIAL
Laishun Chen, William M Greenberg, Carl Gommoll, Joann O'Connor, Stephen R Zukin, Antonia Periclou, Parviz Ghahramani
PURPOSE: Levomilnacipran, a selective serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor, is approved for the treatment of major depressive disorder (MDD) in adults. The objectives of this investigation were to characterize the pharmacokinetic (PK) parameters of levomilnacipran in healthy subjects and in patients with MDD and to compare the plasma concentrations observed at clinically effective doses (40-120 mg daily) in MDD patients versus in vitro inhibitory concentration values for NE and 5-HT transporters...
September 2015: Clinical Therapeutics
keyword
keyword
98853
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"